Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CYTO
DateTimeSourceHeadlineSymbolCompany
20/12/202413:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
20/12/202413:00GlobeNewswire Inc.Altamira Therapeutics Announces Transition from NASDAQ to OTC MarketsNASDAQ:CYTOAltamira Therapeutics Ltd
04/10/202420:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
04/10/202420:01GlobeNewswire Inc.Altamira Therapeutics Provides Update on Nasdaq ListingNASDAQ:CYTOAltamira Therapeutics Ltd
27/09/202413:01GlobeNewswire Inc.Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal SprayNASDAQ:CYTOAltamira Therapeutics Ltd
24/09/202412:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
24/09/202412:01GlobeNewswire Inc.Altamira Therapeutics Provides Business Update and First Half 2024 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
20/09/202413:01GlobeNewswire Inc.Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024NASDAQ:CYTOAltamira Therapeutics Ltd
19/09/202420:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
19/09/202420:01GlobeNewswire Inc.Altamira Therapeutics Announces Closing of up to $12.0 Million Public OfferingNASDAQ:CYTOAltamira Therapeutics Ltd
18/09/202420:19Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CYTOAltamira Therapeutics Ltd
18/09/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTOAltamira Therapeutics Ltd
17/09/202421:00GlobeNewswire Inc.Altamira Therapeutics Announces Pricing of up to $12.0 Million Public OfferingNASDAQ:CYTOAltamira Therapeutics Ltd
16/09/202417:55Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:CYTOAltamira Therapeutics Ltd
16/09/202413:29Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:CYTOAltamira Therapeutics Ltd
16/09/202412:30GlobeNewswire Inc.Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East AsiaNASDAQ:CYTOAltamira Therapeutics Ltd
03/09/202413:01GlobeNewswire Inc.Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11NASDAQ:CYTOAltamira Therapeutics Ltd
23/08/202413:01GlobeNewswire Inc.Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and DenmarkNASDAQ:CYTOAltamira Therapeutics Ltd
22/08/202420:53Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:CYTOAltamira Therapeutics Ltd
16/08/202413:01GlobeNewswire Inc.Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited SubstancesNASDAQ:CYTOAltamira Therapeutics Ltd
12/08/202413:02GlobeNewswire Inc.Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor ModelsNASDAQ:CYTOAltamira Therapeutics Ltd
19/07/202413:01GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore NanoparticlesNASDAQ:CYTOAltamira Therapeutics Ltd
15/07/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTOAltamira Therapeutics Ltd
08/07/202421:17Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:CYTOAltamira Therapeutics Ltd
20/06/202413:01GlobeNewswire Inc.Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo ManagementNASDAQ:CYTOAltamira Therapeutics Ltd
28/05/202414:31GlobeNewswire Inc.Altamira Therapeutics Provides Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
23/05/202412:47GlobeNewswire Inc.Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalNASDAQ:CYTOAltamira Therapeutics Ltd
16/05/202420:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
01/05/202412:47GlobeNewswire Inc.Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationNASDAQ:CYTOAltamira Therapeutics Ltd
24/04/202412:47GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CYTO